Common polymorphisms of the peroxisome proliferator-activated receptor-γ (Pro12Ala) and peroxisome proliferator-activated receptor-γ coactivator-1 (Gly482Ser) and the response to pioglitazone in Chinese patients with type 2 diabetes mellitus

Metabolism: Clinical and Experimental

Volumn 59, Issue 8, 2010, Pages 1139-1144

  Hsieh, Ming Chia ^a   Lin, Kun Der ^a   Tien, Kai Jen ^b   Tu, Shih Te ^c   Hsiao, Jeng Yueh ^a   Chang, Shun Jen ^d   Lin, Shiu Ru ^e   Shing, Shih Jang ^a   Chen, Hung Chun ^a  

^a KAOHSIUNG MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c CHANGHUA CHRISTIAN HOSPITAL   (Taiwan)

^d Department of Otorhinolaryngology Head and Neck Surgery   (Taiwan)

^e FOOYIN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE; GLUCOSE; GLYCINE; HEMOGLOBIN A1C; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA COACTIVATOR 1ALPHA; PIOGLITAZONE; PROLINE; SERINE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; ANTIDIABETIC AGENT; GLYCOSYLATED HEMOGLOBIN; HEAT SHOCK PROTEIN; HEMOGLOBIN A1C PROTEIN, HUMAN; PPARGC1A PROTEIN, HUMAN; TRANSCRIPTION FACTOR;

ADULT; ALLELE; ARTICLE; CHINESE; CONTROLLED STUDY; DISEASE ASSOCIATION; FEMALE; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HETEROZYGOTE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; TREATMENT RESPONSE; AGED; ASIAN; BLOOD; GENETICS; MIDDLE AGED;

ADULT; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; DIABETES MELLITUS, TYPE 2; FEMALE; GENOTYPE; HEAT-SHOCK PROTEINS; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; PPAR GAMMA; THIAZOLIDINEDIONES; TRANSCRIPTION FACTORS;

EID: 77955481012     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.10.030     Document Type: Article

References (31)

1. Lehmann J.M. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor gamma (PPAR gamma) J Biol Chem 270 1995 12953 12956
2. Aronoff S. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group Diabetes Care 23 2000 1605 1611
3. Lawrence J.M., and Reckless J.P. Pioglitazone Int J Clin Pract 54 2000 614 618
4. Scherbaum W.A., and Goke B. Metabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled study Horm Metab Res 34 2002 589 595
5. Herz M. A randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitus Clin Ther 25 2003 1074 1095
6. Phatak H.M., and Yin D.D. Factors associated with the effect-size of thiazolidinedione (TZD) therapy on HbA(1c): a meta-analysis of published randomized clinical trials Curr Med Res Opin 22 2006 2267 2278
7. Yen C.J. Molecular scanning of the human peroxisome proliferator activated receptor gamma (hPPAR gamma) gene in diabetic Caucasians: identification of a Pro12Ala PPAR gamma 2 missense mutation Biochem Biophys Res Commun 241 1997 270 274
8. Deeb S.S. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity Nat Genet 20 1998 284 287
9. Hamann A. Missense variants in the human peroxisome proliferator- activated receptor-gamma2 gene in lean and obese subjects Eur J Endocrinol 141 1999 90 92
10. Ristow M. Obesity associated with a mutation in a genetic regulator of adipocyte differentiation N Engl J Med 339 1998 953 959
11. Barroso I. Dominant negative mutations in human PPARgamma associated with severe insulin resistance, diabetes mellitus and hypertension Nature 402 1999 880 883
12. Shuldiner A.R. Pro115Gln peroxisome proliferator-activated receptor-gamma and obesity Diabetes Care 23 2000 126 127
13. Bluher M., Lubben G., and Paschke R. Analysis of the relationship between the Pro12Ala variant in the PPAR-gamma2 gene and the response rate to therapy with pioglitazone in patients with type 2 diabetes Diabetes Care 26 2003 825 831
14. Kang E.S. Effects of Pro12Ala polymorphism of peroxisome proliferator-activated receptor gamma2 gene on rosiglitazone response in type 2 diabetes Clin Pharmacol Ther 78 2005 202 208
15. Ek J. Mutation analysis of peroxisome proliferator-activated receptor-gamma coactivator-1 (PGC-1) and relationships of identified amino acid polymorphisms to type II diabetes mellitus Diabetologia 44 2001 2220 2226
16. Hara K. A genetic variation in the PGC-1 gene could confer insulin resistance and susceptibility to type II diabetes Diabetologia 45 2002 740 743
17. Nicklas B.J. Genetic variation in the peroxisome proliferator-activated receptor-gamma2 gene (Pro12Ala) affects metabolic responses to weight loss and subsequent weight regain Diabetes 50 2001 2172 2176
18. Vigouroux C. Human peroxisome proliferator-activated receptor-gamma2: genetic mapping, identification of a variant in the coding sequence, and exclusion as the gene responsible for lipoatrophic diabetes Diabetes 47 1998 490 492
19. Iwata E. Mutations of the peroxisome proliferator-activated receptor gamma (PPAR gamma) gene in a Japanese population: the Pro12Ala mutation in PPAR gamma 2 is associated with lower concentrations of serum total and non-HDL cholesterol Diabetologia 44 2001 1354 1355
20. Oh E.Y. Significance of Pro12Ala mutation in peroxisome proliferator-activated receptor-gamma2 in Korean diabetic and obese subjects J Clin Endocrinol Metab 85 2000 1801 1804
21. Lacquemant C. No association between the G482S polymorphism of the proliferator-activated receptor-gamma coactivator-1 (PGC-1) gene and type II diabetes in French Caucasians Diabetologia 45 2002 602 603 [author reply 604]
22. Oberkofler H. Peroxisome proliferator-activated receptor-gamma coactivator-1 gene locus: associations with hypertension in middle-aged men Hypertension 41 2003 368 372
23. Masugi J. Inhibitory effect of a proline-to-alanine substitution at codon 12 of peroxisome proliferator-activated receptor-gamma 2 on thiazolidinedione-induced adipogenesis Biochem Biophys Res Commun 268 2000 178 182
24. Snitker S. Changes in insulin sensitivity in response to troglitazone do not differ between subjects with and without the common, functional Pro12Ala peroxisome proliferator-activated receptor-gamma2 gene variant: results from the Troglitazone in Prevention of Diabetes (TRIPOD) study Diabetes Care 27 2004 1365 1368
25. Ludovico O. Heterogeneous effect of peroxisome proliferator-activated receptor gamma2 Ala12 variant on type 2 diabetes risk Obesity (Silver Spring) 15 2007 1076 1081
26. Florez J.C. Effects of the type 2 diabetes-associated PPARG P12A polymorphism on progression to diabetes and response to troglitazone J Clin Endocrinol Metab 92 2007 1502 1509
27. Puigserver P. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis Cell 92 1998 829 839
28. Kunej T. A Gly482Ser polymorphism of the peroxisome proliferator- activated receptor-gamma coactivator-1 (PGC-1) gene is associated with type 2 diabetes in Caucasians Folia Biol (Praha) 50 2004 157 158
29. Chen S. Peroxisome proliferator-activated receptor-gamma coactivator-1alpha polymorphism is not associated with essential hypertension and type 2 diabetes mellitus in Chinese population Hypertens Res 27 2004 813 820
30. Rosenblatt S. The impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitus Coron Artery Dis 12 2001 413 423
31. Luan J. Evidence for gene-nutrient interaction at the PPARgamma locus Diabetes 50 2001 686 689